Trovafloxacin, levofloxacin and ciprofloxacin: fluoroquinolones. The MIC range and MICs at which 50% and 90% of the tested St Strains are locked shown in Table 1. NCCLS interpretive criteria were used to define groups of antimicrobial susceptibility to penicillin, vancomycin, ampicillin, Danusertib PHA-739358 erythromycin and quinolones. Quinolone-susceptible Gram-positive pathogens. ABT 492 was consistently st Stronger than trovafloxacin, levofloxacin and ciprofloxacin against quinolone-susceptible Gram-positive pathogens. For all species the rank order of potency was ABT 492 trovafloxacin levofloxacin ciprofloxacin. The MIC90s of ABT were 492 for quinolone susceptible strains of staphylococci 0.008 g / ml or less was four times that power hour Ago than that of trovafloxacin.
In Similar way, ABT 492 was four times more active than trovafloxacin against quinolone anf Lligen enterococci, with MIC 90 for Enterococcus faecalis of 0.03 PLX-4720 g / ml and a MIC50 for Enterococcus faecium was 0.25 g / ml ABT 492 two to eight times more active than trovafloxacin against viridans group streptococci, Streptococcus pyogenes, and Listeria monocytogenes. The MIC 90 for quinolone sensitive St Strains of S. pneumoniae was 0.015 g / ml, showing that ABT-492 is 2, 32, and 64 times st Stronger than trovafloxacin, levofloxacin, Figure 1 Structure of ABT 492nd VOL. 47, 2003 In vitro activity of t of ABT 492 3261 TABLE 1 Comparative Example antibacterial activity Th of a type, number of isolates MIC to antibiotics from 50% to 90% of S. aureus ABT 16 492 0.
002 0.008 0.004 0.008 0.008 0.015 0.015 0.03 0.06 0.25 0.12 levofloxacin trovafloxacin 0, 25 0.25 0.5 0.25 0.5 Ciprofloxacin S.aureus ABT 492 19 0.06 0.5 0.12 0.5 0.5 trovafloxacin first February 4 February, 32 levofloxacin, 16 August 8128 32 128 10 S. epidermidis ciprofloxacin ABT 492 0.008 0.008 0.008 0.008 0.06 0.03 0.03 0.06 0.25 0.25 0.25 Levofloxacin Trovafloxacin 0.12 0.25 0 Ciprofloxacin CoNSb ABT 12 0.25 10 492 0.03 0.5 0.25 0.5 trovafloxacin 16th January 8 Levofloxacin in February 4128 8 64 8 32 32 128 S. pneumoniae ciprofloxacin ABT 29 492 0.004 0.03 0.008 0.015 0.015 0.06 0.03 0.03 0.25 1 0.5 0.5 Ciprofloxacin Levofloxacin Trovafloxacin 1 8 1 2 30 S. pneumoniae, ABT 492 0.004 0.5 0.06 0.12 0.12 16 4 8 16 8 16 trovafloxacin levofloxacin 0.5 2 64 32 64 Ciprofloxacin S.
pyogenes ABT 16 492 0.004 0.03 0.008 0.015 0.03 0.12 0.06 0.12 0.25 1 trovafloxacin levofloxacin ciprofloxacin 0.5 0.5 0.25 1 0.5 0.5 10 viridans group streptococci ABT 492 0.004 0.03 0.008 0.015 0.06 0.5 levofloxacin, trovafloxacin 0.12 0.25 1 4 1 2 16 February 4 February 13 ciprofloxacin E. faecalis ABT 492 0.015 0.03 0.03 0.03 0.06 0.25 0.12 0.12 trovafloxacin levofloxacin ciprofloxacin 0.5 1 0.5 1 1 0.5 1 0.25 E . ABT faecalis 12 492 0.06 1 0.25 0.5 0.25 16 4 trovafloxacin 16th January 32 16 32 64 128 2128 levofloxacin ciprofloxacin resistant E. faecium ABT 6492 0.008 0.25 0.25 0.03 2 2 1 0.5 1 0.5 1 1 trovafloxacin levofloxacin ciprofloxacin E. faecium ABT 14 492 0.25 64 0, 5 4 32 32 1128 April 32 levofloxacin, trovafloxacin 32 128 2128128128 ciprofloxacin L. monocytogenes ABT 15 492 0.
06 0.12 0.12 0.12 0.12 0.25 0.25 0.25 1 1 Levofloxacin Trovafloxacin 1 1 2 1 1 E. coli ciprofloxacin ABT 492 20 0.008 0.06 0.015 0.015 trovafloxacin 0.004 0.03 0.008 0.03 0.008 0.03 0.008 0.015 0.004 0.008 0.004 0.008 levofloxacin ciprofloxacin on the n Next page More Nilius et al, 3262 Continued . Antimicrob. Agents Chemother. Table 1: In one species, number of isolates MIC to antibiotics than 50% 9